IL159151A0 - Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments - Google Patents

Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments

Info

Publication number
IL159151A0
IL159151A0 IL15915102A IL15915102A IL159151A0 IL 159151 A0 IL159151 A0 IL 159151A0 IL 15915102 A IL15915102 A IL 15915102A IL 15915102 A IL15915102 A IL 15915102A IL 159151 A0 IL159151 A0 IL 159151A0
Authority
IL
Israel
Prior art keywords
flibanserin
preparation
technical process
preparing medicaments
stable polymorph
Prior art date
Application number
IL15915102A
Other languages
English (en)
Original Assignee
Bidachem Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bidachem Spa filed Critical Bidachem Spa
Publication of IL159151A0 publication Critical patent/IL159151A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL15915102A 2001-08-02 2002-07-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments IL159151A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01118593 2001-08-02
EP01130180 2001-12-19
PCT/EP2002/008466 WO2003014079A1 (en) 2001-08-02 2002-07-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments

Publications (1)

Publication Number Publication Date
IL159151A0 true IL159151A0 (en) 2004-06-01

Family

ID=26076670

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15915102A IL159151A0 (en) 2001-08-02 2002-07-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
IL159151A IL159151A (en) 2001-08-02 2003-12-02 A stable polymorph of flavonosrin, a technical process for its preparation and its use in the preparation of drugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL159151A IL159151A (en) 2001-08-02 2003-12-02 A stable polymorph of flavonosrin, a technical process for its preparation and its use in the preparation of drugs

Country Status (26)

Country Link
EP (2) EP1518858A1 (pl)
JP (1) JP3822601B2 (pl)
KR (1) KR100899297B1 (pl)
CN (1) CN1288147C (pl)
AR (2) AR036208A1 (pl)
AT (1) ATE288911T1 (pl)
AU (1) AU2002331361B2 (pl)
BR (1) BR0211601A (pl)
CA (1) CA2450093C (pl)
CO (1) CO5560572A2 (pl)
DE (1) DE60202958T2 (pl)
DK (1) DK1414816T3 (pl)
EA (1) EA006400B1 (pl)
ES (1) ES2237694T3 (pl)
HR (1) HRP20040107B1 (pl)
HU (1) HU228666B1 (pl)
IL (2) IL159151A0 (pl)
MX (1) MXPA04000913A (pl)
MY (1) MY127294A (pl)
NZ (1) NZ530510A (pl)
PL (1) PL210224B1 (pl)
PT (1) PT1414816E (pl)
RS (1) RS50742B (pl)
SI (1) SI1414816T1 (pl)
UA (1) UA76767C2 (pl)
WO (1) WO2003014079A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
HRP20041092B1 (hr) * 2002-05-22 2013-05-31 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novi farmaceutski pripravci flibanserina
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
JP2009528322A (ja) * 2006-02-28 2009-08-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンによる弁膜性心疾患の治療又は予防
EA200802208A1 (ru) * 2006-05-09 2009-04-28 Бёрингер Ингельхайм Интернациональ Гмбх Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
EP2037927B1 (en) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
AR062320A1 (es) 2006-08-14 2008-10-29 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022932A2 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
WO2008061966A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh New use of flibanserin
US8722682B2 (en) 2006-12-20 2014-05-13 Sprout Pharmaceuticals, Inc. Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
WO2017128932A1 (zh) * 2016-01-31 2017-08-03 孟晓明 氟班色林的新晶型及其制备方法及其用途
CN111303043A (zh) * 2019-04-19 2020-06-19 武汉万知化工医药有限公司 一种氟班色林盐酸盐的制备方法
CN115919860B (zh) 2022-12-05 2023-11-10 中国药科大学 氟班色林在制备治疗雄激素脱发药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
PL210224B1 (pl) 2011-12-30
JP2004537597A (ja) 2004-12-16
RS50742B (sr) 2010-08-31
EA200400252A1 (ru) 2004-08-26
CN1551879A (zh) 2004-12-01
PL364598A1 (pl) 2004-12-13
HK1070063A1 (en) 2005-06-10
EP1414816A1 (en) 2004-05-06
WO2003014079A1 (en) 2003-02-20
HRP20040107A2 (en) 2004-06-30
HUP0401201A2 (hu) 2004-10-28
EA006400B1 (ru) 2005-12-29
EP1518858A1 (en) 2005-03-30
NZ530510A (en) 2004-07-30
CN1288147C (zh) 2006-12-06
CA2450093C (en) 2008-09-23
PT1414816E (pt) 2005-04-29
WO2003014079A8 (en) 2003-11-20
HU228666B1 (en) 2013-05-28
DE60202958D1 (de) 2005-03-17
AU2002331361B2 (en) 2008-06-05
UA76767C2 (uk) 2006-09-15
YU7804A (sh) 2006-08-17
HUP0401201A3 (en) 2004-11-29
KR20040023704A (ko) 2004-03-18
AR077416A2 (es) 2011-08-24
HRP20040107B1 (hr) 2012-02-29
ATE288911T1 (de) 2005-02-15
CA2450093A1 (en) 2003-02-20
ES2237694T3 (es) 2005-08-01
SI1414816T1 (en) 2005-06-30
MXPA04000913A (es) 2004-10-27
CO5560572A2 (es) 2005-09-30
KR100899297B1 (ko) 2009-05-26
IL159151A (en) 2009-09-22
DK1414816T3 (da) 2005-04-11
DE60202958T2 (de) 2006-04-06
BR0211601A (pt) 2004-08-24
JP3822601B2 (ja) 2006-09-20
AR036208A1 (es) 2004-08-18
EP1414816B1 (en) 2005-02-09
MY127294A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
HUP0401201A3 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
ZA200405029B (en) 17α-Alkyl-17β-oxy-estratrienes and intermediates for the production thereof, and use of said 17α-alkyl-17β-oxy-estratrienes for producing medicaments and pharmaceutical preparations
AU2002365516A1 (en) Benzamide derivatives, processes for their preparation, and their pharmaceutical use
HUP0402264A3 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof
HUP0204226A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
PL396568A1 (pl) Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny
IL158289A (en) Mercaptoacetylamide derivatives, a process for their preparation and their use as medicaments for the treatment of hypertension and chf
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
TWI345975B (en) Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
HUP0202233A3 (en) Derivatives and analogues of galanthamin, their use, pharmaceutical compositions containing them and process for the preparation of them
HUP0301075A3 (en) Diphenyl ether derivatives, their use for preparation of pharmaceutical compositions and process for preparation the compounds
HUP0401369A3 (en) Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof
HUP0500958A2 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them
HUP0303804A3 (en) Ligands of the avss6 integrin, process for their preparation, their use and pharmaceutical compositions containing them
IL158587A0 (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
TWI346113B (en) Stable polymorph of flibanserin, technical process for its preparation and use thereof for preparing medicaments
IL152751A0 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
IL160606A0 (en) C2-substituted indan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals
IL157272A0 (en) Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds
HUP0201992A3 (en) Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing the compounds and their use
IL160608A0 (en) C2-substituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals
NO20040403L (no) Stabil polymorf av flibanserin, teknisk fremgangsmåte for fremstilling derav og anvendelse derav for fremstlling av medikamenter